Potential impact of a point-of-care high-sensitivity cardiac troponin assay on emergency department length of stay and patient disposition: findings from a cardiac emergency department Authors: Robert Meek, Zhong Xian Lu, Udara Dilrukshi Senarathne, Sean Tan, Louise Cullen, John W Pickering, Martin Paul Than, Georgina Hayden, Adam Damianopoulos, Claire Charteris, Alex Duong, Diana Egerton-Warburton Published: 2025 The emergency department (ED) use of safe and time-efficient 0-1-hour assessment algorithms for suspected myocardial infarction (MI) is recommended.1 However, laboratory-based high-sensitivity cardiac troponin (hs-cTn) results are often not available within 1 hour from blood draw.2 Point-of-care (POC) hs-cTn assays, with shorter turnaround times (TATs), would solve this problem.2 One study has reported reduced ED length of stay (LOS) from POC-hs-cTnI use in routine clinical care.3 At the Victorian Heart Hospital ED (Monash Health, Australia), we evaluated one of the available POC-hs-cTnI assays, the TriageTrue analyser (QuidelOrtho Corporation, San Diego, California, USA), for which evidence of benefits in actual practice remains limited.4 5 We compared the potential LOS which could result from POC use with the actual LOS using our laboratory Access hsTnI assay.6 Characteristics of both assays are defined and publicly available.6 The study was approved by the institutional ethics committee as a quality assurance project not requiring patient consent. Patients having single and/or serial laboratory-hs-cTnI tests in the ED for suspected MI were recruited when the research clinician was present to run the POC tests (weekdays 11:00–20:00, June–November 2024). Patients with ST-elevation MI were excluded, as were those with single POC tests when serial laboratory tests were done. The study population was those recruited to a concurrent validation study of POC diagnostic accuracy for MI, for which about 1500 patients were required. From the bloods routinely collected by nurses, 0.2 mL was retained for POC testing, which was performed within 4 hours, as per the recommended sample stability time. POC results were not available to treating clinicians. For the primary outcome, the POC TAT was defined as a constant of 20 min (2 min processing plus 18 min assay time, which was the time observed during the study). It was assumed arrival-to-sample-collection and result-to-departure times would remain unchanged with POC use, meaning actual-potential LOS change stemmed solely from the difference between laboratory and POC TATs. The potential and actual LOS was calculated separately for four disposition/testing subgroups: patients admitted or discharged after single or serial hs-cTnI tests. Secondarily, we explored how result discrepancies between laboratory and POC-hs-cTnI testing might impact disposition decision-making. Demographic and clinical information was obtained from the electronic medical record (EMR, Cerner Corporation, North Kansas City, Missouri, USA). Laboratory results and result availability times were obtained from the laboratory information system. MI presence was determined by consensus between an independent cardiologist and an emergency physician using the fourth universal definition of MI. Recorded medical history, laboratory hs-cTnI and other test results were considered, but the reviewers were blinded to the POC hs-cTnI results. The EMR, which covers attendances at all Monash Health sites, was re-checked at 30-days post-index attendance for occurrence of post-discharge MI or death. Of 1213 enrolled patients, 792 (65.3%) had paired single laboratory/POC tests, with 639 (80.7%) being discharged. Of 421 (34.7%) with paired serial laboratory/POC tests, 268 (63.7%) were discharged (figure 1). Median patient age was 64 years, 655 (54.0%) were male, 44 (3.6%) had MI and 4 (0.3%) had 30-day post-discharge MI or death (table 1, figure 1). Mean LOS reductions were 29 (95% CI: 28 to 31) and 37 (95% CI: 32 to 42) min per patient for those discharged after single and serial hs-cTnI testing, respectively (table 2). With POC use, a discrepant result around the upper reference limit may have resulted in 21 discharged patients being admitted (one having 30-day post-discharge MI), and 21 admitted patients being discharged (online supplemental figure 1). Patient flow. ED, emergency department; MI, myocardial infarction; POC, point-of-care; STEMI, ST-elevation MI. Table 1Patient characteristics and outcomesTotal populationN=1213Age64 (50–76)Male sex655 (54.0)Cardiac risk factors and/or comorbiditiesHypertension586 (48.3)Hypercholesterolaemia561 (46.3)Diabetes mellitus287 (23.7)Obesity111 (9.2)Current smoker113 (9.3)Known coronary artery disease372 (30.7)Prior coronary artery stenting or bypass grafting262 (21.6)Prior peripheral arterial vascular disease58 (4.8)Prior stroke53 (4.4)Family history of coronary artery disease89 (7.3)Dialysis for chronic kidney failure6 (0.5)Admitted306 (25.2)MI diagnosis44 (3.6)Inpatient MI or death (all cause) (n=306)10 (3.2)Post-discharge MI or death (all cause) to 30-days (n=1213)4 (0.3)All results are n (%) except age=median (IQR).MI, myocardial infarction. Patient characteristics and outcomes All results are n (%) except age=median (IQR). MI, myocardial infarction. Table 2Length of stay components in minutes for those admitted and discharged after having single baseline or serial troponin tests in the emergency departmentDisposition and testArrival to baseline samplingTest turnaround timeArrival to result availableResult available to ED departureTotal ED LOSMedian of paired LOS differencesMean LOS reduction per patientAdmitted after single hs-cTnIN=153Laboratory testing38 (24–54)48 (39–57)88 (73–108)275 (127–504)360 (226–603)28 (19–37)32 (27 to 38)POC testing20*58 (44–74)331 (186–562)Discharged after single hs-cTnIN=639Laboratory testing40 (27–57)45 (37–57)87 (74–106)113 (57–235)210 (151–330)25 (17–37)29 (28 to 31)POC testing20*60 (47–77)178 (121–298) Disposition and test Arrival to second sampling Second test turnaround time Arrival to second result available Second result available to ED departure Total ED LOS Median of paired LOS differences Mean LOS reduction per patient Admitted after serial hs-cTnIN=153Laboratory testing146 (111–185)52 (42–61)208 (169–247)273 (128–588)484 (333–800)31 (23–40)36 (32 to 39)POC testing20*166 (131–205)459 (291–760)Discharged after serial hs-cTnIN=268Laboratory testing130 (103–178)49 (42–60)186 (152–232)115 (54–268)321 (237–479)29 (21–40)37 (32 to 42)POC testing20*150 (123–198)288 (207–432)All times are median (IQR) other than mean (95% CI) length of stay change per patient.*The POC test turnaround time, being a fixed 20 min (2 min processing plus 18 min assay-time, which was the time observed during the study), has no IQR.ED, emergency department; hs-cTn, high-sensitivity cardiac troponin; LOS, length of stay; POC, point-of-care. Length of stay components in minutes for those admitted and discharged after having single baseline or serial troponin tests in the emergency department All times are median (IQR) other than mean (95% CI) length of stay change per patient. The POC test turnaround time, being a fixed 20 min (2 min processing plus 18 min assay-time, which was the time observed during the study), has no IQR. ED, emergency department; hs-cTn, high-sensitivity cardiac troponin; LOS, length of stay; POC, point-of-care. Use of the POC assay could reduce mean ED LOS by 29–37 min per patient, depending on the disposition/testing subgroup. As the likely impact of these reductions on ED crowding and patient flow is debatable, concurrent system/practice redesign should be considered to further increase LOS reductions.2 Discrepant laboratory-POC results which might impact disposition decision-making were infrequent. Evaluation of POC cost implications, and risks/benefits of ED nurses performing the POC tests, was beyond our scope, and our fixed POC TAT is not guaranteed in practice. In conclusion, POC hs-cTnI assays could deliver reductions in ED LOS, but accompanying system/practice changes, which may be required to deliver whole ED benefits in real-world practice, require investigation. Supplementary material Footnotes Funding: Quidel/Ortho Diagnostics loaned 10 Triage MeterPro POC analysers and trained the research clinicians on TriageTrue use at no cost. Sufficient testing cassettes required for approximately 1500 study patients were provided at no cost by Quidel/Ortho Diagnostics. Provenance and peer review: Not commissioned; externally peer reviewed. Handling editor: Edward Carlton Patient consent for publication: Not applicable. Contributors: The study was conceived by RM, GH, ADa, CC, ZXL, UDS, ST and LC. ADa, CC and GH were responsible for study conduct. RM, UDS, ST, ADu and ZXL were responsible for data collection and the initial statistical analysis. MPT, JWP, LC and DE-W contributed further to the statistical analysis and manuscript. All authors contributed to the final manuscript for which RM takes overall responsibility. Data availability statement The data that support the findings of this study are available from the corresponding author upon reasonable request. References Associated Data Supplementary Materials Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.